Rosiglitazone doesn't increase the amount of a specific sodium channel protein in urine of insulin-resistant people.
Scientific Claim
In 12 insulin-resistant nondiabetic adults, 9 weeks of rosiglitazone (4 mg twice daily) is not associated with changes in urinary α-ENaC levels compared to placebo.
Original Statement
“Furthermore, rosiglitazone did not change either amiloride-induced natriuresis nor the amount of urinary α-ENaC.”
Evidence Quality Assessment
Claim Status
overstated
Study Design Support
Design cannot support claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The abstract uses causal language ('changed'), but the study design is a cohort study without confirmed RCT details, so causation cannot be established; the claim should use association language.
Evidence from Studies
Supporting (1)
Preserved response to diuretics in rosiglitazone-treated subjects with insulin resistance: a randomized double-blind placebo-controlled crossover study